Skip to main content
SpringerLink
Log in

Medication-Assisted Treatment for Opioid Use Disorders 2: Detoxification

  • Chapter
  • First Online:
Opioids

  • 1026 Accesses

Abstract

This chapter is the second of two parts describing the advantages, standards, and goals of medication-assisted treatment (MAT) for opioid use disorders. MAT is a complex biopsychosocial intervention with the provision of opioid substitution treatment (OST) at its core. These chapters aim to provide the clinician with charts, tables, and clinical guidance around the prescribing of OST within MAT. This second part (this chapter) covers the process of detoxification from OST as well as aftercare including the use of naltrexone. This chapter also looks at the care of special patient groups requiring MAT, such as those who are pregnant or who have multiple substance dependencies and gives brief guidance around the management of comorbid mental health problems. These chapters focus on the prescribing issues within MAT and are not able to cover the full scope of the social and psychological aspects of this complex intervention; clinicians are recommended to read broadly to ensure they understand the full scope of MAT, which is far more than just the prescribing of OST.

Data presented here is based on clinical guidelines and the experience in treating persons with OUDs in Scotland, United Kingdom (UK), and reflects evolution in practice in response to the high levels of drug deaths and Scottish national MAT standards published in May 2021. Within the UK, the National Health Service (NHS) exists as a single-payer healthcare system, providing universal care to all residents. This of course is not the case worldwide, and there is substantial variation in availability of services between countries. Clinicians should always ensure that they are familiar with what services are available locally as well as local licensing and legal requirements around prescribing OST, as substitute medications are usually controlled drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kuszmaul AK, Palmer EC, Frederick EK. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: a systematic review. J Am Pharm Assoc. 2020;60(1):145–52.

    Article  Google Scholar 

  2. Crumb MW, Atkinson TJ, et al. Comparing lofexidine and clonidine for opioid withdrawal management [Internet]. Pract Pain Manag. 20(4). [cited 2021 Nov 30]. Available from: https://www.practicalpainmanagement.com/treatments/addiction-medicine/comparison-alpha-2-adrenergic-receptor-agonists-managing-opioid-withdr.

  3. Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998;50(3):251–4.

    Article  CAS  PubMed  Google Scholar 

  4. NICE. Overview | Drug misuse in over 16s: opioid detoxification | Guidance | NICE [Internet]. [cited 2021 Nov 30]. Available from: https://www.nice.org.uk/guidance/cg52.

  5. GOV.UK. Routes to recovery from substance addiction [Internet]. [cited 2021 Sept 14]. Available from: https://www.gov.uk/government/publications/routes-to-recovery-from-substance-addiction.

  6. McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177–87.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Irvine MA, Buxton JA, Otterstatter M, Balshaw R, Gustafson R, Tyndall M, et al. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Lancet Public Health. 2018;3(5):e218–25.

    Article  PubMed  Google Scholar 

  8. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tzemis D, Al-Qutub D, Amlani A, Kesselring S, Buxton JA. A quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program. CMAJ Open. 2014;2(3):E153–61.

    Article  PubMed  PubMed Central  Google Scholar 

  10. GOV.UK. Naloxone: a review [Internet] [cited 2021 Jun 27]. Available from: https://www.gov.uk/government/publications/naloxone-a-review.

  11. World Health Organization. Community management of opioid overdose [Internet]. Geneva: World Health Organization; 2014 [cited 2021 Jun 27]. Available from: https://apps.who.int/iris/handle/10665/137462.

  12. Rando J, Broering D, Olson JE, Marco C, Evans SB. Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths. Am J Emerg Med. 2015;33(9):1201–4.

    Article  PubMed  Google Scholar 

  13. Fisher R, O’Donnell D, Ray B, Rusyniak D. Police officers can safely and effectively administer intranasal naloxone. Prehosp Emerg Care. 2016;20(6):675–80.

    Article  PubMed  Google Scholar 

  14. Kitch BB, Portela RC. Effective use of naloxone by law enforcement in response to multiple opioid overdoses. Prehosp Emerg Care. 2016;20(2):226–9.

    Article  PubMed  Google Scholar 

  15. Hulin J, Brodie A, Stevens J, Mitchell C. Prevalence of respiratory conditions among people who use illicit opioids: a systematic review. Addiction (Abingdon, England). 2020;115(5):832–49.

    Article  Google Scholar 

  16. Tashkin DP. Heroin smoking and COPD: a case for targeted screening spirometry. Chest. 2019;155(2):247–8.

    Article  PubMed  Google Scholar 

  17. Nightingale R, Mortimer K, Giorgi E, Walker PP, Stolbrink M, Byrne T, et al. Screening heroin smokers attending community drug clinics for change in lung function. Chest. 2020;157(3):558–65.

    Article  PubMed  Google Scholar 

  18. Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA. 2016;316(3):282–90.

    Article  PubMed  Google Scholar 

  19. Tanum L, Solli KK, Latif Z-E-H, Benth JŠ, Opheim A, Sharma-Haase K, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiat. 2017;74(12):1197–205.

    Article  Google Scholar 

  20. Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2019;393(10173):778–90.

    Article  CAS  Google Scholar 

  21. Soyka M. Recent advances in the treatment of opioid use disorders. Tech Neurosurg Neurol. 35(5):1–5. https://doi.org/10.31031/TNN.2020.03.000572.

  22. Hwang CS, Bremer PT, Wenthur CJ, Ho SO, Chiang S, Ellis B, et al. Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality. Mol Pharm. 2018;15(3):1062–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bremer PT, Janda KD. Conjugate vaccine immunotherapy for substance use disorder. Pharmacol Rev. 2017;69(3):298–315.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bremer PT, Schlosburg JE, Banks ML, Steele FF, Zhou B, Poklis JL, et al. Development of a clinically viable heroin vaccine. J Am Chem Soc. 2017;139(25):8601–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Nielsen DA, Ji F, Yuferov V, Ho A, Chen A, Levran O, et al. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry. 2008;13(4):417–28.

    Article  CAS  PubMed  Google Scholar 

  26. Bart G, Heilig M, LaForge KS, Pollak L, Leal SM, Ott J, et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry. 2004;9(6):547–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mouly S, Bloch V, Peoc’h K, Houze P, Labat L, Ksouda K, et al. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 2015;79(6):967–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ahmad T, Valentovic MA, Rankin GO. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol. 2018;153:196–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pan Y-X, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci U S A. 2009;106(12):4917–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Doehring A, Oertel BG, Sittl R, Lötsch J. Chronic opioid use is associated with increased DNA methylation correlating with increased clinical pain. Pain. 2013;154(1):15–23.

    Article  CAS  PubMed  Google Scholar 

  31. Chorbov VM, Todorov AA, Lynskey MT, Cicero TJ. Elevated levels of DNA methylation at the OPRM1 promoter in blood and sperm from male opioid addicts. J Opioid Manag. 2011;7(4):258–64.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Nielsen DA, Yuferov V, Hamon S, Jackson C, Ho A, Ott J, et al. Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. Neuropsychopharmacology. 2009;34(4):867–73.

    Article  CAS  PubMed  Google Scholar 

  33. Hwang CK, Kim CS, Kim DK, Law P-Y, Wei L-N, Loh HH. Up-regulation of the mu-opioid receptor gene is mediated through chromatin remodeling and transcriptional factors in differentiated neuronal cells. Mol Pharmacol. 2010;78(1):58–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Oertel BG, Kettner M, Scholich K, Renné C, Roskam B, Geisslinger G, et al. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009;284(10):6530–5.

    Article  CAS  PubMed  Google Scholar 

  35. Ferrer-Alcón M, La Harpe R, García-Sevilla JA. Decreased immunodensities of micro-opioid receptors, receptor kinases GRK 2/6 and beta-arrestin-2 in postmortem brains of opiate addicts. Brain Res Mol Brain Res. 2004;121(1–2):114–22.

    Article  PubMed  Google Scholar 

  36. Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009;29(47):14764–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, et al. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015;12(4):807–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Verdejo-Garcia A, Lorenzetti V, Manning V, Piercy H, Bruno R, Hester R, et al. A roadmap for integrating neuroscience into addiction treatment: a consensus of the neuroscience interest group of the International Society of Addiction Medicine. Front Psych. 2019;10:877.

    Article  Google Scholar 

  39. Verdejo-García A, Pérez-García M. Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components. Psychopharmacology. 2007;190(4):517–30.

    Article  PubMed  Google Scholar 

  40. Rezapour T, DeVito EE, Sofuoglu M, Ekhtiari H. Perspectives on neurocognitive rehabilitation as an adjunct treatment for addictive disorders: from cognitive improvement to relapse prevention. Prog Brain Res. 2016;224:345–69.

    Article  PubMed  Google Scholar 

  41. Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, et al. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. 2014;155(9):1829–35.

    Article  CAS  PubMed  Google Scholar 

  42. Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J, et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171(5):1165–1175.e13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Luigjes J, Segrave R, de Joode N, Figee M, Denys D. Efficacy of invasive and non-invasive brain modulation interventions for addiction. Neuropsychol Rev. 2019;29(1):116–38.

    Article  PubMed  Google Scholar 

  44. Ekhtiari H, Tavakoli H, Addolorato G, Baeken C, Bonci A, Campanella S, et al. Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead. Neurosci Biobehav Rev. 2019;104:118–40.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, et al. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry. 2007;164(1):100–7.

    Article  PubMed  Google Scholar 

  46. Weiss RD, Griffin ML, Jaffee WB, Bender RE, Graff FS, Gallop RJ, et al. A “community-friendly” version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial. Drug Alcohol Depend. 2009;104(3):212–9.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Day E. Routes to recovery via the community. London: Public Health England; 2013.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NHS Borders Addiction Service, Galashiels, Scotland, UK

    James Tidder

  2. University of St Andrews, St Andrews, Scotland, UK

    Alexander M. Baldacchino

  3. NHS Fife Addiction Services, Leven, Scotland, UK

    Alexander M. Baldacchino

  4. Forward Leeds, Leeds, UK

    Joseph Tay Wee Teck

Authors
  1. James Tidder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander M. Baldacchino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph Tay Wee Teck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Tidder .

Editor information

Editors and Affiliations

  1. Department of Pharmacobiology, Cinvestav, Mexico City, Mexico

    Silvia L. Cruz

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tidder, J., Baldacchino, A.M., Teck, J.T.W. (2022). Medication-Assisted Treatment for Opioid Use Disorders 2: Detoxification. In: Cruz, S.L. (eds) Opioids. Springer, Cham. https://doi.org/10.1007/978-3-031-09936-6_15

Download citation

Publish with us

Policies and ethics

Search

Navigation